Bioniche’s Canadian filing for Urocidin delayed

10 October 2013

Canadian biopharma firm Bioniche Life Sciences (TSX: BNC) has provided an update on its plans for a New Drug Submission filing in Canada for Urocidin, the company's Phase III bladder cancer product, indicating a six-month delay.

Urocidin is a formulation of MCNA, a sterile mycobacterial cell wall-nucleic acid composition that has anticancer activity. Previously known as MCC suspension, this name has been changed to reflect thedetailed characterization of MCC suspension following receipt of regulatory feedback.

A failure to gain marketing approval for Urocidin could be devastating for the company, which registers about $1.5 million in loses monthly (about $18 million annually) and deemed to be in “precarious financial position” by one dissident shareholder, according to a recent local media report.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK